查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1807920

生物製药契约製造市场（按服务类型、产品类型、生产阶段、应用和组织规模）—2025-2030 年全球预测

Biopharmaceuticals Contract Manufacturing Market by Service Type, Product Type, Production Stage, Application, Organisation Size - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年生物製药契约製造市场价值将达212亿美元，2025年将成长至231.1亿美元，复合年增长率为9.24%，到2030年将达到360.6亿美元。

主要市场统计数据
基准年2024年 212亿美元
预计2025年 231.1亿美元
预测年份 2030 360.6亿美元
复合年增长率（%） 9.24%

生物製药契约製造领域的开创性进展将催生下一代治疗开发和供应链卓越

生物製药契约製造正在从一种辅助服务模式演变为创新和加速上市的战略推动力。随着从单株抗体到先进细胞和基因疗法等治疗模式日益复杂，外包合作伙伴已不再只是服务供应商，而是成为製剂、製程优化和法规合规的关键合作者。这种转变的驱动力源于先进技术平台的整合、严格的品质要求以及整体研发过程中业务灵活性日益增长的需求。

技术进步和策略联盟推动生物製药契约製造的典范转移，推动产业发生前所未有的变革。

生物製药契约製造製造业正在经历重大变革，这得益于技术突破、策略联盟和监管模式的转变。一次性技术和连续生产方法正在取代传统的不銹钢系统，提高生产线的灵活性并缩短週转时间。人工智慧和高阶分析技术正在整合到品管工作流程中，增强预测性维护并确保批次一致性。

全面评估2025年美国关税对生物製药契约製造供应链和产业动态的影响

2025年美国新关税的实施对全球生物製药契约製造供应链产生了连锁反应。从受影响地区进口的原料和关键试剂将提高关税，导致投入成本上升，并对利润结构造成压力。受託製造製造商正在透过重新评估其供应商组合、探索近岸外包选项以及重新谈判长期供应协议来应对市场波动。

揭示对生物製药契约製造中服务类型、产品类型、生产阶段、应用和组织规模的细分洞察

仔细检视服务类型、产品类型、生产阶段、应用和组织规模，就能发现受託製造领域蕴含的微妙机会与挑战。分析和品管测试仍然是基础，但人们越来越重视能够加速决策的高通量、多属性方法。生技药品製造服务正在不断发展，以支持日益复杂的分子，製程开发和优化倡议正构建为并行工作流，从而实现从实验室规模到中试生产的快速过渡。

揭示美洲、欧洲、中东和非洲以及亚太市场生物製药契约製造的区域动态

区域动态在塑造外包策略和成本结构方面发挥关键作用。美洲地区在合约受託製造能力方面继续遥遥领先，这得益于其强大的合约製造（CMO）生态系统、监管专业知识和成熟的物流网络。同时，欧洲、中东和非洲地区则受益于丰富的专业科学家人才库、部分市场优惠的税收优惠政策，以及强大的产学研合作传统，这些都促进了早期生物工艺创新。

确定塑造全球生物製药契约製造未来的关键创新者和策略合作者

领先的受託製造製造商正凭藉其技术领先地位、不断扩展的生产能力以及与领先生物製药公司和新兴生物技术创新者的战略联盟，脱颖而出。一些供应商正在大力投资一次性生物反应器系统和连续层析法，而另一些供应商则正在利用多属性质谱和自动采样技术来增强其分析测试套件。

为行业领导者提供切实可行的策略，推动不断发展的生物製药契约製造领域的成长和卓越运营

行业领导者必须采取多管齐下的策略，确保韧性并推动成长。投资整合即时流程监控和预测分析的数位平台，将改善决策并降低批次缺陷的风险。结合模组化设备和一次性技术的弹性製造网络，能够提供所需的灵活性，以满足不同临床阶段和治疗模式不断变化的需求。

用于揭示生物製药契约製造研究中关键见解的方法严谨性和创新调查方法

分析基于一种混合调查方法，将严谨的二手资料研究与一手质性访谈结合。透过广泛查阅监管指南、行业白皮书和公司特定出版物，我们对技术趋势和政策变化有了基础性的了解。二级资讯来源经过可信度审查，并与近期同行评审日誌进行交叉引用，以确保事实准确性。

摘要关键发现并综合见解，为生物製药契约製造生态系统的策略决策者提供指导

技术敏捷性日益重要、策略伙伴关係关係发挥关键作用、贸易政策转变中供应链弹性的必要性等等。这些见解强调了受託製造製造商必须超越传统的单一产能模式，并转型为综合创新合作伙伴。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 一次性生物反应器技术在CDMO设施中的快速扩展，以提高生物製药生产的灵活性
  • mRNA 疫苗契约製造需求激增，推动全部区域对 CDMO 产能的投资
  • 透过整合连续单株抗体製造流程提高生产效率
  • 在生物製药 CDMO 中实施高阶分析和人工智慧以进行预测流程优化
  • 生技公司与CDMO建立策略联盟，加速细胞与基因治疗生产
  • 扩大高效和无菌生技药品的合约填充和完成服务，以满足不断变化的监管要求
  • 为了支持基因治疗管道，人们越来越有兴趣将病毒载体生产外包给专门的 CDMO。

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章：生物製药契约製造市场（按服务类型）

  • 分析和品管测试
  • 生物製药製造服务
  • 製程开发与最佳化

第九章生物製药契约製造市场（依产品类型）

  • 细胞和基因治疗
    • CAR-T疗法
    • 基因编辑疗法
  • 单株抗体
  • 重组蛋白
    • 酵素
    • 荷尔蒙
  • 疫苗
    • mRNA疫苗
    • 蛋白质次单元疫苗
    • 病毒载体疫苗

第 10 章生物製药契约製造市场（按生产阶段）

  • 临床
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 商业的

第 11 章生物製药契约製造市场（按应用）

  • 自体免疫疾病
  • 心血管系统
  • 感染疾病
    • 细菌
    • 寄生虫
    • 病毒性的
  • 神经病学
  • 肿瘤学

第 12 章生物製药契约製造市场（依公司规模）

  • 大型组织
  • 小型企业

13.美洲生物製药契约製造市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 14 章欧洲、中东和非洲生物製药契约製造市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

15. 亚太生物製药契约製造市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十六章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AbbVie, Inc.
    • Ajinomoto Co., Inc.
    • 3P Biopharmaceuticals
    • Aenova Group GmbH
    • AGC Biologics
    • Aurobindo Pharma Limited
    • Boehringer Ingelheim International GmbH
    • Cambrex Corporation
    • Catalent, Inc.
    • Celonic AG
    • FUJIFILM Diosynth Biotechnologies
    • INCOG BioPharma Services, Inc.
    • JRS PHARMA GmbH+Co. KG
    • KBI Biopharma Inc
    • Lonza AG
    • Merck KGaA
    • Pressure BioSciences, Inc. by Emergent Health Corp.
    • ProBioGen AG
    • Rentschler Biopharma SE
    • Samsung Biologics
    • Thermo Fisher Scientific Inc.
    • Toyobo Co., Ltd.
    • WuXi Biologics, Inc.

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

Product Code: MRR-8C74ADFC15ED

The Biopharmaceuticals Contract Manufacturing Market was valued at USD 21.20 billion in 2024 and is projected to grow to USD 23.11 billion in 2025, with a CAGR of 9.24%, reaching USD 36.06 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 21.20 billion
Estimated Year [2025] USD 23.11 billion
Forecast Year [2030] USD 36.06 billion
CAGR (%) 9.24%

Pioneering Evolution in Biopharmaceutical Contract Manufacturing to Unlock Next Generation Therapeutic Development and Supply Chain Excellence

The contract manufacturing landscape for biopharmaceuticals has evolved from a supplementary service model to a strategic enabler of innovation and speed to market. As therapeutic modalities grow increasingly complex, from monoclonal antibodies to advanced cell and gene therapies, outsourcing partners are no longer mere service providers but critical collaborators in formulation, process optimization, and regulatory compliance. This transformation has been driven by the convergence of advanced technology platforms, stringent quality requirements, and a rising demand for operational flexibility across the development continuum.

Leading biopharmaceutical developers are leveraging partnerships to navigate the intricate balance between cost pressures and the imperative for high-quality output. The reliance on specialized analytical and quality control testing has intensified, while end-to-end biologics manufacturing services have become central to scaling promising drug candidates. Process development and optimization efforts are now pursued in tandem with regulatory authorities to expedite clinical transitions without compromising safety or efficacy.

Against this backdrop, contract manufacturing organizations are positioning themselves as full-spectrum partners capable of supporting both early-stage clinical objectives and high-volume commercial supply. This introduction lays the groundwork for understanding the strategic imperatives shaping the industry and sets the stage for examining the key forces, segmentation insights, and recommendations that follow.

Shifting Paradigms in Biopharmaceutical Contract Manufacturing as Technological Advances and Strategic Collaborations Drive Unprecedented Industry Transformation

The biopharmaceutical contract manufacturing sector is experiencing a profound shift catalyzed by technological breakthroughs, strategic alliances, and changing regulatory paradigms. Single-use technologies and continuous manufacturing approaches are replacing legacy stainless-steel systems, lending agility to production lines and reducing turnaround times. Artificial intelligence and advanced analytics are being integrated into quality control workflows to enhance predictive maintenance and ensure batch consistency.

These advancements coincide with a trend toward personalized medicine, prompting contract manufacturers to develop modular facility designs capable of handling small-batch, high-complexity products alongside traditional biologics. Partnerships between emerging cell and gene therapy innovators and established contract organizations are proliferating, driven by a mutual need for specialized expertise in vector production and cryopreservation protocols.

Simultaneously, regulatory bodies across major markets are issuing guidance that emphasizes process transparency and real-time monitoring. This regulatory evolution has spurred contract providers to adopt digital platforms that facilitate data integrity and compliance tracking. Consequently, the landscape is no longer defined solely by capacity but by the ability to deliver quality outcomes, accelerate timelines, and co-innovate with development partners.

Evaluating the Comprehensive Consequences of the 2025 United States Tariffs on the Biopharmaceutical Contract Manufacturing Supply Chain and Industry Dynamics

The introduction of new United States tariffs in 2025 has generated a ripple effect across the global supply chain for biopharmaceutical contract manufacturing. Raw materials and critical reagents imported from impacted regions are subject to increased duties, leading to elevated input costs and exerting pressure on margin structures. Contract manufacturing organizations have responded by reevaluating supplier portfolios, exploring nearshoring options, and renegotiating long-term supply agreements to buffer against volatility.

Smaller biotechnology firms, which often depend on specialized laboratory reagents and single-use components sourced abroad, find themselves particularly exposed to these cumulative duties. In contrast, larger organizations with diversified supplier networks and in-house formulation capabilities are better positioned to absorb or mitigate the cost burden. Nevertheless, both cohorts are experiencing longer lead times and heightened logistical complexity, underscoring the importance of supply chain resilience.

To alleviate the impact of tariff-driven cost increases, outsourced manufacturing partners are prioritizing process intensification and yield enhancement strategies. By optimizing upstream cell culture conditions and refining downstream purification steps, contract providers can reduce overall material consumption and partially offset higher procurement costs. These measures, combined with strategic inventory management, are essential for maintaining competitiveness in an environment shaped by trade policy shifts.

Revealing Segmentation Insights in Biopharmaceutical Contract Manufacturing across Service and Product Types Production Stages Applications and Organisation Sizes

A granular examination of service type, product type, production stage, application, and organisation size reveals nuanced opportunities and challenges within the contract manufacturing domain. Analytical and quality control testing remains foundational, with emerging emphasis on high-throughput, multi-attribute methods that accelerate decision making. Biologics manufacturing services are evolving to support increasingly complex molecules, while process development and optimization initiatives are being structured as parallel workstreams, enabling faster transitions from bench scale to pilot production.

On the product front, cell and gene therapies demand specialized vector production capabilities, encompassing CAR T therapy workflows and precise gene editing protocols. Monoclonal antibodies continue to benefit from well-established platform processes, whereas recombinant proteins, including enzymes and hormones, leverage optimized expression systems to achieve high yields. Vaccines represent another dynamic segment, with mRNA constructs, protein subunit platforms, and viral vector approaches each requiring distinct manufacturing know-how.

Across clinical and commercial production stages, the industry demonstrates divergent priorities. Phase I through Phase III clinical batches focus on agility and regulatory alignment, whereas commercial manufacturing emphasizes cost efficiencies and scale. Therapeutic applications span autoimmune disorders, cardiovascular diseases, infectious diseases with bacterial, parasitic, and viral strains, neurology, and oncology, each presenting unique quality and safety considerations. Finally, large organisations seek full-service partnerships for end-to-end supply security, while small and medium enterprises often prioritize flexible, project-based engagements to support innovation without heavy capital investment.

Uncovering Regional Dynamics in Biopharmaceutical Contract Manufacturing Spanning the Americas Europe Middle East Africa and Asia Pacific Markets

Regional dynamics play a pivotal role in shaping outsourcing strategies and cost structures. The Americas continue to command significant contract manufacturing capacity, supported by a robust ecosystem of CMOs, regulatory expertise, and established logistics networks. Conversely, Europe, Middle East & Africa benefit from a rich pool of specialized scientific talent, favorable tax incentives in select markets, and a strong tradition of academic-industry collaborations that fuel early-stage bioprocess innovation.

Asia-Pacific has emerged as a growth epicenter, propelled by manufacturing cost arbitrage, government-backed infrastructure investments, and a burgeoning domestic pipeline of biotechnology ventures. Contract providers in this region are expanding capacity to accommodate global demand, introducing state-of-the-art aseptic filling suites and advanced analytics platforms. Simultaneously, regional regulatory authorities are harmonizing standards with international guidelines, simplifying cross-border transfers and bolstering global supply chain integration.

This geographic tapestry underscores the need to align outsourcing decisions with regional strengths. Manufacturing in North America may offer shorter lead times and streamlined regulatory pathways, while partnerships in Europe, Middle East & Africa grant access to specialized services and collaborative research frameworks. Meanwhile, Asia-Pacific is carving out a dual role as both a cost-competitive production hub and a fast-growing market for biologic products, reshaping global capacity dynamics.

Identifying Leading Innovators and Strategic Collaborators Shaping the Future of Biopharmaceutical Contract Manufacturing Worldwide

Leading contract manufacturing organizations have distinguished themselves through technological leadership, capacity footprint, and strategic alliances with both large biopharmaceutical firms and emerging biotech innovators. Several providers have invested heavily in single-use bioreactor systems and continuous chromatography, while others have enhanced their analytical testing suites with multi-attribute mass spectrometry and automated sampling technologies.

Strategic collaborations between CMO partners and academic institutions have accelerated the translation of novel modalities such as gene-edited cell therapies, enabling seamless technology transfer and risk-sharing models. Service providers with modular facility designs offer cost-efficient options for early-stage developers, while those operating mega-scale commercial sites cater to high-volume monoclonal antibody and vaccine production. Additionally, partnerships with reagent manufacturers and equipment suppliers have strengthened supply chain resilience and fostered co-innovation.

The competitive landscape is further shaped by the pursuit of sustainability credentials, with top companies adopting green chemistry principles, carbon-neutral facility operations, and circular single-use plastics recycling programs. These strategic differentiators enhance brand reputation and meet the rising expectations of stakeholders seeking environmentally responsible outsourcing partners.

Actionable Strategies for Industry Leaders to Drive Growth and Operational Excellence in the Evolving Biopharmaceutical Contract Manufacturing Landscape

Industry leaders must adopt a multi-pronged approach to secure resilience and drive growth. Investing in digital platforms that integrate real-time process monitoring with predictive analytics will sharpen decision making and reduce batch failure risks. Flexible manufacturing networks, combining modular facilities and single-use technologies, offer the agility needed to address fluctuating demand profiles across clinical phases and therapeutic modalities.

Formulating collaborative frameworks that incentivize joint process development and shared risk can accelerate time-to-clinic and optimize capital allocation. Leaders should also explore strategic alliances that extend beyond capacity, encompassing co-development partnerships, reagent co-investment, and joint intellectual property arrangements. Diversifying supply chains through geographic dispersion will mitigate tariff impacts and logistical disruptions.

Equally vital is cultivating talent with cross-functional expertise in bioprocess engineering, data science, and regulatory affairs. By fostering a culture that values continuous improvement and open innovation, organizations can maintain operational excellence while adapting to evolving market demands. Embracing sustainability initiatives will further differentiate service offerings and align with corporate social responsibility objectives, ensuring long-term stakeholder value creation.

Methodological Rigor and Innovative Research Techniques Employed to Uncover Critical Insights in Biopharmaceutical Contract Manufacturing Studies

This analysis is grounded in a hybrid research methodology that blends rigorous secondary research with primary qualitative interviews. An extensive review of regulatory guidelines, industry white papers, and proprietary company publications provided the foundational understanding of technological trends and policy shifts. Secondary data sources were vetted for credibility and cross-referenced against recent peer-reviewed journals to ensure factual accuracy.

Complementing this desk research, structured interviews were conducted with C-suite executives, process engineers, regulatory experts, and supply chain managers. These engagements offered nuanced perspectives on strategic imperatives, operational bottlenecks, and partnership models. Triangulation of quantitative and qualitative inputs enabled the identification of high-impact trends and actionable insights.

Key findings were further validated through a collaborative workshop with industry practitioners, where preliminary conclusions were stress-tested against real-world scenarios. This iterative approach ensured that recommendations are both grounded in empirical evidence and aligned with the strategic priorities of today's biopharmaceutical developers and contract manufacturing providers.

Summarizing Key Findings and Synthesizing Insights to Guide Strategic Decision Makers in the Biopharmaceutical Contract Manufacturing Ecosystem

In synthesizing the findings, several core themes emerge: the rising importance of technological agility, the critical role of strategic partnerships, and the necessity of supply chain resilience amid shifting trade policies. These insights underline the imperative for contract manufacturing organizations to transcend traditional capacity-only models and evolve into integrated innovation partners.

Segmentation analysis highlights that while monoclonal antibodies and recombinant proteins maintain established manufacturing platforms, cell and gene therapies and novel vaccine modalities demand bespoke process development expertise. Regional dynamics signal that Asia-Pacific is poised for rapid expansion, whereas Europe, Middle East & Africa will continue to offer strategic centers of excellence in early-stage development.

For decision makers, the convergence of digitalization, sustainability demands, and evolving tariff landscapes mandates a holistic strategy. By aligning service portfolios with emerging product trends, diversifying geographic footprints, and investing in cutting-edge process technologies, organizations can position themselves for long-term success. The insights presented serve as a blueprint for navigating the next chapter of biopharmaceutical contract manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid expansion of single-use bioreactor technologies in CDMO facilities to increase biopharmaceutical production flexibility
  • 5.2. Surging contract manufacturing demand for mRNA vaccines driving CDMO capacity investments across regions
  • 5.3. Integration of continuous manufacturing processes for monoclonal antibodies to enhance production efficiency
  • 5.4. Adoption of advanced analytics and artificial intelligence for predictive process optimization in biopharma CDMOs
  • 5.5. Strategic partnerships between biotech firms and CDMOs to accelerate cell and gene therapy manufacturing readiness
  • 5.6. Expansion of contract fill-finish services for high-potency and sterile biologics to meet evolving regulatory demands
  • 5.7. Growing interest in outsourcing viral vector production to specialized CDMOs to support gene therapy pipelines

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Biopharmaceuticals Contract Manufacturing Market, by Service Type

  • 8.1. Introduction
  • 8.2. Analytical & Quality Control Testing
  • 8.3. Biologics Manufacturing Service
  • 8.4. Process Development & Optimization

9. Biopharmaceuticals Contract Manufacturing Market, by Product Type

  • 9.1. Introduction
  • 9.2. Cell And Gene Therapy
    • 9.2.1. CAR T Therapy
    • 9.2.2. Gene Editing Therapy
  • 9.3. Monoclonal Antibodies
  • 9.4. Recombinant Proteins
    • 9.4.1. Enzymes
    • 9.4.2. Hormones
  • 9.5. Vaccines
    • 9.5.1. mRNA Vaccines
    • 9.5.2. Protein Subunit Vaccines
    • 9.5.3. Viral Vector Vaccines

10. Biopharmaceuticals Contract Manufacturing Market, by Production Stage

  • 10.1. Introduction
  • 10.2. Clinical
    • 10.2.1. Phase I
    • 10.2.2. Phase II
    • 10.2.3. Phase III
  • 10.3. Commercial

11. Biopharmaceuticals Contract Manufacturing Market, by Application

  • 11.1. Introduction
  • 11.2. Autoimmune Disorders
  • 11.3. Cardiovascular
  • 11.4. Infectious Diseases
    • 11.4.1. Bacterial
    • 11.4.2. Parasitic
    • 11.4.3. Viral
  • 11.5. Neurology
  • 11.6. Oncology

12. Biopharmaceuticals Contract Manufacturing Market, by Organisation Size

  • 12.1. Introduction
  • 12.2. Large Organisation
  • 12.3. Small & Medium Organisation

13. Americas Biopharmaceuticals Contract Manufacturing Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Biopharmaceuticals Contract Manufacturing Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie, Inc.
    • 16.3.2. Ajinomoto Co., Inc.
    • 16.3.3. 3P Biopharmaceuticals
    • 16.3.4. Aenova Group GmbH
    • 16.3.5. AGC Biologics
    • 16.3.6. Aurobindo Pharma Limited
    • 16.3.7. Boehringer Ingelheim International GmbH
    • 16.3.8. Cambrex Corporation
    • 16.3.9. Catalent, Inc.
    • 16.3.10. Celonic AG
    • 16.3.11. FUJIFILM Diosynth Biotechnologies
    • 16.3.12. INCOG BioPharma Services, Inc.
    • 16.3.13. JRS PHARMA GmbH + Co. KG
    • 16.3.14. KBI Biopharma Inc
    • 16.3.15. Lonza AG
    • 16.3.16. Merck KGaA
    • 16.3.17. Pressure BioSciences, Inc. by Emergent Health Corp.
    • 16.3.18. ProBioGen AG
    • 16.3.19. Rentschler Biopharma SE
    • 16.3.20. Samsung Biologics
    • 16.3.21. Thermo Fisher Scientific Inc.
    • 16.3.22. Toyobo Co., Ltd.
    • 16.3.23. WuXi Biologics, Inc.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: RESEARCHAI
  • FIGURE 26. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: RESEARCHSTATISTICS
  • FIGURE 27. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: RESEARCHCONTACTS
  • FIGURE 28. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL & QUALITY CONTROL TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT & OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CAR T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CAR T THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GENE EDITING THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GENE EDITING THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ENZYMES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MRNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARASITIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY LARGE ORGANISATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY LARGE ORGANISATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL & MEDIUM ORGANISATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL & MEDIUM ORGANISATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 181. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 182. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 199. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 200. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 201. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 202. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORGANISATION SIZE, 2025-2030 (USD MILLION)
  • TABLE 253. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 255. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELL AND GENE THERAPY, 2025-2030 (USD MILLION)
  • TABLE 259. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2030 (USD MILLION)
  • TABLE 261. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 262. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
  • TABLE 263. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2018-2024 (USD MILLION)
  • TABLE 264. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION STAGE, 2025-2030 (USD MILLION)
  • TABLE 265. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL, 2025-2030 (USD MILLION)
  • TABLE 267. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. GERMANY BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY BIOPH